You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test, which is being developed with a National Science Foundation grant, is based on a novel PCR technology that doesn't require traditional instrumentation.
The real-time RT-PCR LightMix Ebola Zaire test runs on the Roche Light Cycler 480 or Cobas Z 480 instruments.
The RNAi-based drug is designed to specifically target the strain of the virus responsible for the current outbreak.
The money from the Massachusetts Life Sciences Center will go toward developing a test that does not require laboratory instrumentation.
The award will go to David Alland to create an Ebola test using the same technology as a TB assay marketed by Cepheid.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
BioInnovation Solutions, formerly Pathogenica, and Enzymatics are developing a rapid Ebola diagnostic and have validated it on patient samples in Nigeria.
The tests use the company's Nanotrap reagents, hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
Qiagen announced today it will offer global distribution of the Altona Diagnostics RealStar Ebolavirus RT-PCR Kit 1.0.
The firms intend to seek Emergency Use Authorization from the US Food and Drug Administration once the Ebola assay is developed.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
Time magazine looks into how liquid biopsies are changing cancer care.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.